Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003873 (rheumatoid arthritis)
 53,068 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 88.9% of a group of 18 patients with rheumatoid arthritis participating in an open-label study with fenoprofen calcium (Nalfon), there was observed a mean titre decrease in level of rheumatoid factor as compared to baseline levels. In follow-up, three months to one year later, a uniform titre increase above the mean level of the study period had occurred. In all cases the titre returned to baseline levels or higher.
 ...
PMID:The effect of fenoprofen calcium (Nalfon) on levels of rheumatoid factor in patients with rheumatoid arthritis. 33 91

Fenoprofen calcium (FC) was compared to aspirin (ASA) in 20 patients with rheumatoid arthritis in a double-blind parallel study. The average daily dose was 2.0 gm of FC, or 3.6 gm of ASA. Most patients on FC therapy responded similarly to those receiving ASA, but FC was slightly better in reducing morning stiffness, walking time, fatigue severity, and activity index. More FC treated than ASA treated patients became worse when placebo was substituted after one year of therapy, with a greater increase in the number and severity of painful and swollen joints, in addition to the above mentioned parameters. This suggests a greater suppression of the inflammatory process during FC therapy. FC was well tolerated and had a greater antirheumatic effect than aspirin. Both drugs were superior to placebo.
 ...
PMID:Fenoprofen calcium therapy in rheumatoid arthritis. 78 Dec 26

Fenoprofen calcium was compared with acetylsalicylic acid in the treatment of 27 patients with definite or classic rheumatoid arthritis, over a period of one year. Both drugs appeared efficacious, with a slight edge to fenoprofen in the doses employed. Fewer side effects were noted with fenoprofen. Effectiveness continued undiminished throughout the year, and mean values of most parameters continued to improve in both groups over the entire period. Three problems which influence extrapolation of results from this and similar studies to the general setting are discussed. (1) Individual patients show great variation from the mean and from one observation point to another. Thus, expectations developed from mean values will seldom be accurate in a particular patient. (2) The relative doses chosen for two drugs in the clinical trial can profoundly influence both efficacy and toxicity. The qualification "at the doses employed" is seldom emphasized in clinical reports. (3) Patient compliance in the general clinical setting is importantly different from that in a clinical trial, and this potential problem must be assessed by the physician choosing an appropriate medication for a particular patient.
 ...
PMID:Some problems in the interpretation of clinical trials: longterm parallel study of fenoprofen in rheumatoid arthritis. 78 Dec 32